Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 51 to 60 of 542 total matches.
Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
antihistamine/corticosteroid combination
to be approved for this indication; azelastine 0.1%/
fluticasone ...
The FDA has approved Ryaltris (Hikma), a fixed-dose
combination nasal spray containing the H1-antihistamine olopatadine hydrochloride (Patanase,
and generics) and the corticosteroid mometasone
furoate (Nasonex 24 HR Allergy, and generics), for
treatment of seasonal allergic rhinitis symptoms
in persons ≥12 years old. Ryaltris is the second
intranasal antihistamine/corticosteroid combination
to be approved for this indication; azelastine 0.1%/fluticasone propionate (Dymista, and generics), which
is approved for use in persons ≥6 years old, was the
first. Both products are available...
Med Lett Drugs Ther. 2023 Jan 23;65(1668):12-4 doi:10.58347/tml.2023.1668c | Show Introduction Hide Introduction
Ozanimod (Zeposia) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021 (Issue 1633)
Ozanimod (Zeposia) for Ulcerative Colitis
The oral sphingosine 1-phosphate (S1P) receptor ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator ozanimod (Zeposia – Bristol Myers Squibb)
has been approved by the FDA for treatment of adults
with moderately to severely active ulcerative colitis. It
is the first S1P receptor modulator to be approved for
treatment of ulcerative colitis. Ozanimod was approved
in March 2020 for use in adults with relapsing forms of
multiple sclerosis.
Bremelanotide (Vyleesi) for Hypoactive Sexual Desire Disorder
The Medical Letter on Drugs and Therapeutics • Jul 29, 2019 (Issue 1577)
; flibanserin
(Addyi), which was approved in 2015, was the first.1
Pronunciation Key
Bremelanotide: bre” me ...
The FDA has approved bremelanotide (Vyleesi – Amag),
a melanocortin receptor agonist, for subcutaneous
treatment of premenopausal women with acquired,
generalized hypoactive sexual desire disorder (HSDD).
Bremelanotide is not approved for use in men or
postmenopausal women. It is the second drug to
be approved in the US for this indication; flibanserin
(Addyi), which was approved in 2015, was the first.
Adult Immunization
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022 (Issue 1661)
of certain vaccines in adults
residing in the US.1 Routine childhood immunization
has reduced the overall ...
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these vaccine-preventable diseases, but many
adults remain susceptible. Recommendations for
vaccination against COVID-19, seasonal influenza,
and monkeypox and vaccination of travelers have
been reviewed separately.
Comparison Table: Some Oral Drugs for Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • Apr 19, 2021 (Issue 1622)
/pseudoephedrine –
Zyrtec-D 12 hour (Johnson & Johnson)
5 mg/120 mg ER tabs OTC 1 tab bid ≥12 yrs: 1 tab bid ...
View the Comparison Table: Some Oral Drugs for Allergic Rhinitis
Dasiglucagon (Zegalogue) for Severe Hypoglycemia
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021 (Issue 1631)
,
an intranasal powder approved for use in patients
≥4 years old, have been available since 2019.1,2
Injectable ...
The FDA has approved dasiglucagon (Zegalogue –
Zealand) for subcutaneous (SC) treatment of severe
hypoglycemia in patients ≥6 years old with diabetes.
Dasiglucagon is the third glucagon product to be
marketed in the US that does not require reconstitution
before administration; Gvoke, a SC formulation approved for use in patients ≥2 years old, and Baqsimi,
an intranasal powder approved for use in patients
≥4 years old, have been available since 2019.
Injectable glucagon emergency kits (GlucaGen
HypoKit, and generics) have been available for years,
but they require...
Vibegron (Gemtesa) for Overactive Bladder
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
to
be approved in the US; mirabegron (Myrbetriq) was
the first.1
STANDARD TREATMENT — Overactive bladder (OAB ...
The FDA has approved the selective beta-3 adrenergic
agonist vibegron (Gemtesa – Urovant Sciences)
for treatment of overactive bladder in adults with
symptoms of urge urinary incontinence, urgency, and
urinary frequency. It is the second beta-3 agonist to
be approved in the US; mirabegron (Myrbetriq) was
the first.
Paxlovid for Treatment of COVID-19
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
Authorization (EUA) for the investigational
antiviral drug nirmatrelvir copackaged with the HIV-1
protease ...
On December 22, 2021, the FDA issued an Emergency
Use Authorization (EUA) for the investigational
antiviral drug nirmatrelvir copackaged with the HIV-1
protease inhibitor ritonavir (Paxlovid – Pfizer) for
oral treatment of mild to moderate COVID-19 in
outpatients ≥12 years old who weigh at least 40 kg
and are at high risk of progressing to severe disease,
including hospitalization or death. Paxlovid was the
first oral antiviral drug to be authorized in the US for
treatment of COVID-19; Merck's oral antiviral drug
molnupiravir was granted an EUA for treatment of
COVID-19 on...
An EUA for Bamlanivimab - A Monoclonal Antibody for COVID-19
The Medical Letter on Drugs and Therapeutics • Nov 30, 2020 (Issue 1612)
to severe disease and/or hospitalization (see Table 1).1 Monoclonal antibodies, such as bamlanivimab ...
The investigational neutralizing IgG1 monoclonal
antibody bamlanivimab (LY-CoV555; Lilly) has
been granted an FDA Emergency Use Authorization
(EUA) for treatment of recently diagnosed mild
to moderate COVID-19 in patients who are ≥12
years old, weigh at least 40 kg, and are at high
risk for progressing to severe disease and/or
hospitalization (see Table 1).
A Dexamethasone Ophthalmic Insert (Dextenza) for Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • Mar 20, 2023 (Issue 1672)
of allergic conjunctivitis was based
on the results of 3 randomized, double-masked
trials (1 published; 2 ...
The FDA has approved Dextenza (Ocular Therapeutix),
a dexamethasone ophthalmic insert, for
treatment of ocular itching associated with allergic
conjunctivitis. Dextenza was approved earlier for
treatment of ocular inflammation and pain following
ophthalmic surgery.
Med Lett Drugs Ther. 2023 Mar 20;65(1672):45-6 doi:10.58347/tml.2023.1672b | Show Introduction Hide Introduction